Subunit Vaccines for Herpes Viruses and Methods of Use
AssigneeJuvaris Biotherapeutics, Inc. the Trustees of the University of Pennsylvania
InventorsJeffery Fairman, Gary H. Cohen, Roselyn J. Eisenberg
Life of this patent
Estimating the term…
Abstract
The present disclosure generally relates to vaccine compositions for Herpes Simplex Viruses (HSV) types 1 and/or 2. The vaccines comprise isolated antigens or glycoprotein subunits of the viruses, optionally with an adjuvant, such as a cationic liposome DNA complex (CLDC). Also the present disclosure contains methods of vaccinating a subject utilizing these compositions.
Claims48
A composition of isolated Herpes Simplex Virus (HSV) antigens comprising an isolated glycoprotein B (gB) or a fragment thereof, and an isolated glycoprotein H (gH) or a fragment thereof in a complex with glycoprotein L (gL) of a fragment thereof.
A method for vaccinating a mammalian subject against HSV comprising concurrently or sequentially administering to the subject an effective amount of an isolated glycoprotein B (gB) or a fragment thereof in an adjuvant, and an isolated glycoprotein H (gH) or a fragment thereof in a complex with glycoprotein L (gL) of a fragment thereof, wherein the complex is in an adjuvant.
An isolated nucleic acid molecule consisting essentially of a nucleotide sequence encoding glycoprotein B (gB) or a fragment thereof, in-frame with a nucleotide sequence encoding glycoprotein H (gH) or a fragment thereof, and in-frame with a nucleotide sequence encoding glycoprotein L (gL) or a fragment thereof.
An isolated nucleic acid molecule consisting essentially of a nucleotide sequence encoding glycoprotein B (gB) or a fragment thereof, in-frame with a nucleotide sequence encoding glycoprotein H (gH) or a fragment thereof, in-frame with a nucleotide sequence encoding glycoprotein L (gL) or a fragment thereof, and in-frame with a nucleotide sequence encoding glycoprotein D (gD) or a fragment thereof.
A composition comprising an isolated nucleic acid molecule encoding a glycoprotein B (gB) or a fragment thereof, and an isolated nucleic acid molecule encoding a glycoprotein H (gH) or a fragment thereof, and an isolated nucleic acid molecule encoding glycoprotein L (gL) or a fragment thereof.
A method for vaccinating a mammalian subject against HSV-2 comprising concurrently or sequentially administering to the subject an effective amount of an isolated nucleic acid molecule encoding a glycoprotein B (gB) or fragment thereof complexed with a cationic liposome delivery vehicle, and an isolated nucleic acid molecule encoding a glycoprotein H (gH) or fragment thereof in combination with an isolated nucleic acid molecule encoding a glycoprotein L (gL) or fragment thereof, wherein the combination is complexed with a cationic liposome delivery vehicle.
Dependencies are inferred from the claim text.